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Abstract: Background. Parotidectomy is a common proce-
dure and Frey’s syndrome (gustatory sweating) is a common
side effect. The current literature was assessed concerning the
effectiveness of the sternocleidomastoid muscle (SCM) ﬂap to
prevent Frey’s syndrome after parotidectomy.
Methods. A bibliography search was conducted for studies
published between 1966 and 2010 and included randomized
controlled trials (RCTs) or cohort studies with patients under-
going parotidectomy with facial nerve preservation. The out-
come measures of particular interest were the incidence of
Frey’s syndrome and cosmetic impairment.
Results. In all, 12 studies were selected (1 meta-analysis
of all interventions to prevent Frey’s syndrome, 2 RCTs, and 9
cohort studies). The trials were too heterogeneous to perform a
meta-analysis on the effect of the SCM ﬂap. The results
reported by the authors of each study suggest an objective
decrease in Frey’s syndrome when the SCM ﬂap was used,
but there was no difference in the patients’ subjective reporting
of symptoms. However, this conclusion is prone to the biases
inherent in these studies, and thus overall it is impossible to
make any recommendation.
Conclusion. Current reported evidence is inconclusive
as to the use of SCM muscle ﬂap as an intervention to
prevent Frey’s syndrome following parotid surgery. VC 2011
Wiley Periodicals, Inc. Head Neck 34: 589–598, 2012
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Parotidectomy is a common surgical procedure whose
indications are mainly primary salivary gland neo-
plasms and metastatic skin cancer. Salivary gland
tumors are most often benign neoplasms, and in that
long-term patient survival is to be anticipated, conse-
quent long-term postoperative complications may lead
patients to present for advice and treatment. One of
the most common late complications following parotid
surgery is the auriculotemporal nerve syndrome
or gustatory sweating, also known as Frey’s syn-
drome, in honor of Łucja (Lucie) Frey, who described
its nosology in 1923.1–3
Andre Thomas4 in 1927 and later Ford and Wood-
hall5 in 1938 postulated the theory of aberrant regen-
eration of the sectioned parasympathetic ﬁbers that
regrow to innervate the vessels and sweat glands of
the skin overlying the parotid to explain the symptoms.
Injury to the auriculotemporal nerve ﬁbers and/or
parasympathetic ﬁbers in the facial nerve during
parotidectomy probably damages the secretomotor ac-
tivity of the parotid gland. In the process of nerve
regeneration, parasympathetic secretomotor ﬁbers
may become misdirected and grow along distal cut
ends of sympathetic ﬁbers to the skin vessels and
sweat glands. A new salivary reﬂex is made possible
and gustatory stimulus produces sweating and ﬂush-
ing. This regeneration process takes a certain amount
of time, suggesting a latent period between
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intraoperative auriculotemporal nerve injury and the
onset of Frey’s syndrome. The reported incidence of
gustatory sweating after parotidectomy is highly vari-
able (2% to 80%) and ‘‘depends on the diligence with
which it is sought and the time-interval from surgery.’’1
Many surgeons accept that most patients will have a
positive Minor’s test but also a minority will look for
speciﬁc treatment of symptoms. In most reports, this
interval ranges from 2 weeks to 2 years, although la-
tency periods of >8 years have been reported.6 The ma-
jority of patients suffering from this phenomenon will
have symptomatic Frey’s syndrome at 12 months fol-
lowing surgery, that is, gustatory sweating in 80%,
skin erythema in 40%, and reported increased skin
temperature in 20%.7,8 In 1 study, 40% of the sympto-
matic patients had 2 or more symptoms, but fewer
than 10% sought treatment.7 However, 96% of patients
who were objectively tested for gustatory sweating
(objective Frey’s syndrome shown by a starch-iodine
test or Minor’s test) tested positive, and the total area
of sweating covered a mean area of 18 cm2.7 Once pres-
ent, the gustatory sweating and ﬂushing seems to
remain unchanged, even after many years.9 Studies
have shown that the clinical severity of Frey’s syn-
drome correlates with the surface area involved7,10 and
the extent of the parotid surgery (superﬁcial or total).11
There has also been an ongoing debate on the role of
the thickness of the ﬂap raised prior to parotidec-
tomy,12 suggesting that a thicker ﬂap will be more
effective, but this has not been substantiated by other
authors.7,13 It is agreed by clinicians that some
patients suffer from considerable social embarrass-
ment and social incapacity arising from profuse ﬂush-
ing and sweating when eating, and some have
attempted to measure these effects,14 although there is
for now no globally recognized standardized question-
naire for quality of life in Frey’s syndrome.2 Because
not all patients develop gustatory sweating after parot-
idectomy, and even among those who do, not all com-
plain or require treatment; thus, selection of patients
for appropriate use of preventative surgical measures
is problematic.2 A recent publication suggests that sur-
geons should engage patients in a dialogue of the oper-
ative risks, beneﬁts, and alternatives relating to the
use of surgical techniques to prevent Frey’s syndrome.
The uncertainty regarding the signiﬁcance of Frey’s
syndrome postoperatively makes the informed consent
process and preoperative decision making complex.15
Many authors have tried to assess different surgi-
cal procedures to avoid the onset of this complication.
The most common recommended procedures are the
interposition of musculoaponeurotic ﬂaps between the
skin and the parotid bed, to interrupt the aberrant
innervation of the skin.16–29 These ﬂaps can use the
superﬁcial musculoaponeurotic system (SMAS) ﬂap,
the temporoparietal ﬂap, or the sternocleidomastoid
muscle (SCM) ﬂap. Although there are many studies
analyzing this question, they provide contradictory
results and have small samples sizes with conse-
quently low statistical power. Other strategies have
been reported in the literature to prevent Frey’s syn-
drome. In the United States, the use of allogenic acel-
lular dermis or free or vascularized fat grafts to
provide a barrier is popular and is widely used.30–32
The aim of this study was to assess the effective-
ness of the SCM ﬂap to prevent Frey’s syndrome after
parotidectomy. The use of the SCM ﬂap has many
advantages over the SMAS ﬂap, as a potential
decrease in the cosmetic defect, less risk of skin inju-
ries during ﬂap design, minimal risk of late skin ne-
crosis, an ability to provide a larger width and length
of muscle tissue that can be interposed, and ease with
ﬂap design and axis of rotation after parotidectomy.
MATERIALS AND METHODS
A bibliography search on MEDLINE and EMBASE
databases for studies published from January 1966 to
August 2010 using the terms parotidectomy, Frey’s
syndrome, complications, parotid gland, surgery, and
gustatory sweating. An expanded search was used
with each relevant article using Boolean operators.
References were explored to identify other articles.
We included only studies published in the English
language.
Study Selection. After a preliminary search, all
abstracts were reviewed by the authors, and those
that dealt with operative procedures to prevent Frey’s
syndrome were selected for further analysis. Criteria
for inclusion of studies in the review were: random-
ized controlled trials (RCTs) or cohort designs that
included patients with benign or malignant parotid
tumors who underwent partial or total parotidectomy
with facial nerve preservation. Studies that included
patients with previous surgical procedures in the pa-
rotid area or with previous radiotherapy were
excluded. Interventions analyzed were SCM ﬂaps
(added or not to SMAS ﬂap) compared with no ﬂap.
The main outcome was incidence of Frey’s syndrome,
determined with subjective or objective measures,
with individual analysis of each outcome. Methods of
detection of Frey’s syndrome (objective or subjective)
and time to follow-up were speciﬁcally recorded. The
secondary outcome was cosmetic impairment that
was noted when they were reported in the studies.
Investigators acquired data about sample size,
patients characteristics, surgical procedures, outcome
evaluation methods, and frequency of Frey’s syn-
drome. The methodologic quality of each study was
assessed in accord with Cochrane Collaboration
guidelines for RCTs (details of randomization method,
allocation concealment, blind evaluation of outcomes,
intention to treat analysis, and loss to follow-up), giv-
ing a qualiﬁcation of risk of bias. For cohort designs,
we used the guidelines of the STROBE33 initiative
(eligibility criteria, variables and confounders, and
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length and loss to follow-up). Methodologic and clini-
cal weaknesses were discussed.
Data from each study were extracted by reviewers
for calculation of odds ratio (OR) using a 2  2 table.
Stratiﬁcation by design and quality of the studies
were made to analyze the main outcome. If clinical
and methodologic heterogeneity was not found, a
meta-analysis of results was attempted. In the other
cases, heterogeneity was explained. Recommendations
were classiﬁed in accord with level of evidence and
GRADE34 methodology.
RESULTS
The initial search gave 236 articles. In all, 63 studies
were excluded because they were not published in Eng-
lish. After reviewing the abstracts, 12 were selected for
this review,8,13,16–21,23,35–37 resulting in only 1 meta-
analysis and 2 RCTs.8,10 The other studies were non-
randomized clinical trials. Table 18,16–21,23,35–37 shows
the characteristics of each primary study.
Nonrandomized Clinical Trials. The ﬁrst study was
reported by Kornblut et al37 with a similar incidence
of objective Frey’s syndrome (97% in the ﬂap group vs
91% in the no ﬂap group) and a higher incidence in
subjective Frey’s syndrome for the ﬂap group (40% vs
14%). This study retrospectively selected a random
sample of patients but did not report inclusion or
exclusion criteria. They clearly reported a selection
bias, and age and sex were not reported. The article
described that the ﬂap was designed to cover the
branches of the auriculotemporal nerve. In accord
with the technique of the ﬂap, the ﬁgures and the
text suggest that the ﬂap could be shorter than
needed ‘‘but it was primarily placed to cover the
branches of the auriculotemporal nerve emerging
from the retromandibular fossa,’’ leaving some periph-
eral branches of the facial nerve without coverage,
which theoretically allows a contact between the
nerve and the subcutaneous tissue and skin. Kornblut
et al37 present graphics adjusted by year of presenta-
tion. Most objective Frey’s syndromes were classiﬁed
as minimal (58%), and subjective complaints occurred
primarily in patients objectively classiﬁed as moder-
ate or severe. There was no information about compli-
cations associated with the ﬂap.
The second study was reported by Casler and
Conley,23 which does not describe either the clinical
characteristics of the patients or the methods of selec-
tion of patients or ﬂap indications, which introduces
an important selection bias. The authors showed a
lower risk of subjective Frey’s syndrome in the ﬂap
group (12.5% vs 47.1%), without objective measures,
and state that there was ‘‘no functional defect of mov-
ing the SCM muscle, nor was there a cosmetic defor-
mity in the neck’’ and no complications.
The third study was made by Sood et al.20 There
were no reported criteria for inclusion or reasons to
select patients for the ﬂap. They excluded patients
with conditions that could confound the evaluation of
Frey’s syndrome (as malignancy, diabetes, previous
surgery, and medicaments) and selected those with
>12 months of follow-up. This is the ﬁrst study to
include an objective measurement of the outcome
using Minor’s starch-iodine test, but evaluators were
not blind to the intervention. They found a lower inci-
dence of objective Frey’s syndrome (18.2% vs 81.8%;
p<.05) and subjective Frey’s syndrome (0% vs 18.2%)
for patients undergoing SCM ﬂap interposition. The
study reported no complication in the ﬂap group, but
did not show objective measures.
The fourth study by Kim and Mathog21 included
only benign or low-grade malignancies. They also
included a subjective measure of the face contour
with a severity scale as a cosmetic outcome. However,
the authors did not report the clinical characteristics
of the patients, and ﬂap interposition was based on
patient acceptance of the procedure. Together with
the SCM ﬂap, the surgical technique added a wide
SMAS ﬂap including the platysma muscle. The inci-
dence of subjective Frey’s syndrome was lower for the
ﬂap group (22% vs 50%). The contour appearance
reported by patients was normal in 4 of 9 patients
(44%) (1 hardly noticeable) in the ﬂap group com-
pared with 5 of 10 patients (50%) in the no ﬂap group
(7 moderate or hardly noticeable). There was no
report about complications with the ﬂap.
The ﬁfth study by Gooden et al19 gave no clear
inclusion or exclusion criteria, and had a rate of
recruitment of 43%. This fact could introduce an im-
portant selection bias. The authors used subjective
evaluation of cosmetic appearance by the patient and
an objective measurement using an observer-rated
disﬁgurement scale with blind evaluators. The inci-
dence of objective Frey’s syndrome was similar
between groups (31% vs 31%) but the incidence of
subjective Frey’s syndrome was higher in the ﬂap
group (31% vs 23%). The subjective report of cosmetic
satisfaction (54% vs 54%) and the objective rating by
external examiners was similar for patients (13
patients in the no ﬂap group vs 12 in the ﬂap group
had a score <3).
The sixth study by Filho et al17 had a recruitment
rate of 31%. The only inclusion criteria were benign
tumors and agreement to participate, but there was no
information about other selection criteria or indica-
tions to perform a SCM ﬂap; however, the study also
included malignant tumors. Clinical characteristics of
the patients were not reported. The muscle covered
the whole defect. The incidence of objective Frey’s syn-
drome (0% vs 36.8%) and subjective Frey’s syndrome
(0% vs 47.4%) was higher in the no ﬂap group.
The seventh study be Fee and Tran36 had as
inclusion criteria living close to Stanford University,
total parotidectomy, benign or low-grade malignant
tumor, and acceptance to participate. However,
the authors included patients undergoing revision
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surgery. They included a subjective evaluation of cos-
metic appearance and an evaluation by blind exami-
ners on a scale from 1 to 10. They reported that the
ﬂap was ﬁxed to the zygomatic arch and masseter mus-
cle. There is no clear indication about the coverage of
the surgical bed, but the photograph suggests it cov-
ered the entire defect. The incidence of objective Frey’s
syndrome was similar between groups (20% vs 22%)
but the subjective incidence was higher in the no ﬂap
group (13% vs 44%). The cosmetic evaluation showed
higher values for the reconstruction group (8.7 vs 7.7
for the frontal view and 8.3 vs 6.2 for the oblique
view). There was no difference in facial paresis rate
(4.8% for the ﬂap group vs 7.2% for the no ﬂap group),
but there was more numbness in the territory of the
great auricular nerve in the ﬂap group (100% vs 78%).
The eighth study by Zhao et al35 did not offer in-
formation about other inclusion or exclusion criteria.
Photographs showed a complete coverage of the surgi-
cal bed. Cosmetic appearance was assessed using the
depth of the postoperative concavity. The incidence of
objective Frey’s syndrome was higher for the ﬂap
group (45% vs 37%), although subjective Frey’s syn-
drome was similar between groups (25% vs 22%).
Concavity measurements were higher for the no ﬂap
group (19–28 mm vs 5–6 mm). Complications were
not different between the groups.
The ninth study by Rustemeyer et al8 did not
offer information about the SCM ﬂap indications.
Patient clinical characteristics and the type of sur-
gery were included. The incidence of subjective
Frey’s syndrome was similar between groups (24.1%
vs 21.9%). There was no report of objective Frey’s
syndrome or complications.
RandomizedControlled Trials andMeta-analysis. The
ﬁrst RCT was published by Kerawala et al18 in 2002.
The authors did not offer information about inclusion
or exclusion criteria. The randomization method by
odds and evens carried a high risk of bias. There was
no information about allocation concealment. The
analysis was made per protocol with a high risk of
bias. Clinical characteristics of patients were
reported. The ﬂap covered the entire surgical defect.
Cosmetic appearance was assessed with a visual
analog scale by the patients and physicians blind to
the intervention (range 0¼normal appearance to
5¼severe asymmetry). The incidence of objective
Frey’s syndrome was higher in the ﬂap group (90% vs
73%; p¼.21), but the incidence of subjective Frey’s
syndrome was higher in the no ﬂap group (38% vs
60%; p¼.31). Patient evaluation of cosmetic appear-
ance was 1.5 for the ﬂap group versus 2.6 for the no
ﬂap group and physician evaluation found 2.8 versus
3.5, respectively, but the differences were not statisti-
cally signiﬁcant. There were no differences regarding
the rates of facial nerve paralysis.
The second RCT published by Asal et al16 appeared
in 2005. There was no other information about inclu-
sion or exclusion criteria. Clinical characteristics of
the patients were clearly reported. Information about
randomization and allocation concealment was lack-
ing. Evaluation of the outcomes was made by physi-
cians blind to the intervention. The analysis was made
by intention to treat. They compared the addition of
an SCM ﬂap to an SMAS ﬂap. Cosmetic appearance
was assessed subjectively by patients and the physi-
cians, but the methods were not clearly reported. The
incidence of objective Frey’s syndrome was higher in
the no ﬂap group (0% vs 50%), but the incidence of
subjective Frey’s syndrome was similar between
groups (0% vs 0%). The evaluation of cosmetic appear-
ance by patients and physicians (a score of 50% for the
ﬂap group vs 58% for the no ﬂap group) was similar
between groups. Complications were stated to be simi-
lar but without objective data.
The only existing meta-analysis was published in
2009 by Curry et al13 and included 15 prospective and
retrospective studies with 1078 patients, but with dif-
ferent surgical techniques (SCM ﬂap, SMAS ﬂap, tem-
poroparietal fascia, parotid gland fascia, dura mater,
polyglactin, or Vycril and polytetraﬂuoroethylene or
GoreTex interposition). The authors concluded that
patients’ complaints or symptoms of Frey’s syndrome
(subjective evaluation) and the results of skin staining
using the Minor starch-iodine test (objective evalua-
tion) were successfully prevented by the interposition
of any tissue with an OR of 3.88 (95% conﬁdence inter-
val [CI] 2.81–5.34) and 3.66 (2.32–5.77), respectively.
This study has important methodologic weaknesses,
however. First, it included observational and experi-
mental studies, which can bias results because of
intrinsic ﬂaws of the design. There is no evaluation of
the internal validity of each study and the clinical
characteristics of patients and surgical procedures
were highly heterogeneous (64% to 73%).
Individual results are shown in Table 28,16–21,23,35–37
and Figures 18,17,19,20,23,35–37 and 2.17,19,20,35–37 Results
of the trials were too heterogeneous for a meta-analysis
to be possible. Results of the trials suggest a better
objective response with the SCM ﬂap, but without a dif-
ference in subjective response. However, this conclusion
is very prone to bias, making it impossible to make a
recommendation based on statistical evidence.
DISCUSSION
The pathophysiology of Frey’s syndrome was
described in 1927.4 The most accepted explanation for
this syndrome is the aberrant regeneration of the
ﬁbers of the auriculotemporal nerve that go through
the facial nerve to the parotid gland, and that grow to
innervate the sweat glands and blood vessels of
the skin, producing the characteristics of sweating
and ﬂushing of the parotid region during eating.
Accepting this pathophysiology, many surgical
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procedures have been proposed to interpose any tis-
sue between the parotid bed and the skin, such as
SCM, temporoparietal, platysma, and derma ﬂaps, to
prevent the aberrant innervation.18,38–40
The most common procedures performed today
are the SCM ﬂap, the SMAS ﬂap, and the use of acel-
lular dermis. The SCM ﬂap is commonly used because
it is easy to rotate into the parotid region without
another incision, the ﬂap is long enough to cover all
the branches of the facial nerve, the ﬂap decreases
the depression of the surgical area after parotid gland
resection, there is a low risk of necrosis of the ﬂap
because of its vascularization, and there is a low risk
of complications, primarily, spinal accessory nerve
injury. However, there is no strong evidence support-
ing the use of this procedure to prevent Frey’s syn-
drome. Some authors do not recommend it,41 whereas
others use it currently36 based on results of their own
studies. In the era of evidence-based medicine,42 it is
necessary to support most surgical interventions with
strong information about its effectiveness and secu-
rity. Furthermore, other factors such as satisfaction
related to cosmetic appearance and costs should be
assessed because the introduction of a new procedure
Table 2. Incidence of Frey’s syndrome measured objectively and subjectively.
Trial Year
No. of patients with SCM ﬂap No. of patients without SCM ﬂap
No. of patients with SMAS
ﬂap
No. of patients without
SMAS ﬂap
No. of patients with SMAS
ﬂap
No. of patients without
SMAS ﬂap
Total Subjective Objective Total Subjective Objective Total Subjective Objective Total Subjective Objective
Kornblut et al37 1977 35 14 34 35 5 32
Casler and Conley23 1991 16 2 104 49
Kim and Mathog21 1999 9 2 10 5
Sood et al20 1999 11 2 2 11 0 9
Gooden et al19 2001 13 4 4 13 3 4
Kerawala et al18 2002 21 8 19 15 9 11
Fee and Tran36 2004 15 2 3 9 4 2
Filho et al17 2004 24 0 0 19 9 7
Asal et al16 2005 12 0 0 12 0 6
Rustemeyer et al8 2008 203 49 169 37
Zhao et al35 2008 42 2 17 33 17 17 94 5 19 57 28 37
Abbreviations: SCM: sternocleidomastoid muscle; SMAS: superﬁcial musculoaponeurotic system.
FIGURE 1. Results of subjective measurements of Frey’s syndrome in nonrandomized clinical trials. SCM, sternocleidomastoid mus-
cle; SMAS, superﬁcial musculoaponeurotic system.
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could increase operating room time and use of other
resources.43
Our study attempted to identify all studies about
this subject and found 11 studies: 9 observational, 2
RCTs, and 1 systematic review. Curry et al13 published
a meta-analysis in 2009, concluding that operative
techniques, including the SCM ﬂap, decrease the rate
of Frey’s syndrome after parotidectomy. However, this
study has important methodologic weaknesses, such
as combining different surgical techniques, differing
populations and study designs, and, importantly, per-
forming a meta-analysis even after having found a
high heterogeneity, which is not recommended by the
Cochrane Collaboration.44 In our opinion, the clinical
and statistical heterogeneity of these studies makes it
impossible to combine their results in a pooled one,
precluding the use of a meta-analysis to evaluate the
SCM ﬂap as a measure to avoid Frey’s syndrome.45
Most heterogeneity among the studies can be
explained by clinical and methodologic differences.
Many studies are retrospective and cover a long length
of time, with the corresponding risk of recall bias and
the obvious modiﬁcation in surgical technique that
could confound results.46 This fact is connected with
another factor: the follow-up time. It has been shown
that there is a latency of approximately 6 months
before appearance of Frey’s syndrome. If studies do not
have a long enough follow-up the rate of Frey’s syn-
drome would be underestimated. However, it is also
probable that patients with longer follow-up could have
developed a tolerance to the syndrome, considering it
less important, and thus reporting relatively lower sub-
jective symptoms. Interposition of SCM forms a barrier
between the parotid gland and the overlying skin. It is
not clear if this barrier inhibits or only delays aberrant
reinnervation of the skin by parasympathetic nerve
ﬁbers. In different series follow-up is variable and may
be too short to answer this question. If follow-up is
short and no Frey’s syndrome occurs it could wrongly
be concluded that SCM prevents gustatory sweating
instead of delaying it. Therefore, long-term follow-up is
needed to answer the question if interposition of SCM
avoids Frey’s syndrome or just delays it.
Most studies did not establish clear inclusion and
exclusion criteria. This weakness, named ‘‘selection
bias’’ in the epidemiologic literature, is 1 of the most
important biases affecting these studies.44 The inclu-
sion of patients based on nondeﬁned criteria can pro-
duce the imbalanced selection of patients, making
ﬁnal results inexact. The inclusion of patients based in
their agreement to participate allows the inclusion of
certain patients, commonly those with a less severe
condition, underestimating the ﬁnal incidence of the
syndrome. A reporting bias is also associated with sex,
age, and other clinical characteristics of patients.47
Another factor involved the method to detect the
gustatory sweating. The Minor’s or postoperative io-
dine-starch test37 is considered the gold standard to
detect objective Frey’s syndrome. However, there is
no reliable information standardizing the technique
or providing the rate of true and false positives. Some
studies report the incidence of Frey’s syndrome based
on subjective complaints, whereas others used the
more objective method. In accord with the philosophy
FIGURE 2. Results of objective measurements of Frey’s syndrome in nonrandomized clinical trials. SCM, sternocleidomastoid muscle;
SMAS, superﬁcial musculoaponeurotic system.
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of outcomes research43 that considers predominantly
outcomes relevant to patients, it is correct to think
that the real incidence should be based on the
symptoms perceived by the patients because these
cases are those that need speciﬁc treatment. Other im-
portant outcomes such as cosmetic results were meas-
ured in only few studies, and the methods used were
highly subjective and heterogeneous between studies.
Another variable in these studies is the surgical
technique. We chose to evaluate only the SCM ﬂap.
SMAS ﬂaps cannot be used in cases in which the onco-
logic margin includes its resection.25 The SMAS ﬂap
offers the possibility of a better cosmetic result in terms
of decreasing the postoperative depression. Other ﬂaps
such as the temporoparietal ﬂap38 require a wider dis-
section in the temporal area, including an extension of
the incision and a higher risk of damaging the frontal
branch of the facial nerve. The surgical techniques to
design the SCM ﬂap used in the previous studies were
heterogeneous, and it was hard to identify the details
that could standardize the technique. Some authors
used an inferior based ﬂap, whereas others used a
superior-based ﬂap. The studies are ambiguous about
the necessary length of the ﬂap and the need to cover
all of the branches of the facial nerve, avoiding connec-
tion with the skin. Kim and Mathog21 used only the su-
perﬁcial layer of the SCM in their platysma muscle–
cervical fascia–SCM ﬂap. Details about the thickness of
the ﬂap and its vascular pedicle(s) were not adequately
described in most studies. These weaknesses stem from
a lack of standardization of the surgical procedure and
thus a bias in the uniformity of results.
Finally, sample sizes are too small. Lack of statis-
tical power has been widely discussed in the medical
literature.48 This refers to obtaining a negative con-
clusion when it is really positive, the product of a
small population. Most studies included in this review
suffer from lack of power.
Results from this review do not allow any conclu-
sions about the effectiveness of the SCM ﬂap to pre-
vent Frey’s syndrome, which is not the same as
saying that it is not useful. The most important rea-
son is the lack of enough RCTs, which are considered
the highest level of evidence to make decisions. Most
information is taken from observational studies that
are prone to bias. Data about objective measurements
suggest a protective effect, but subjective data are not
conclusive. The cosmetic effect seemed to be more pro-
nounced in the ﬂap group. Nonetheless, systematic
reviews such as ours offer an opportunity not only to
identify weaknesses on actual evidence but also to
provide guidelines to design and develop trials that
could help to solve the problems identiﬁed. Any study
that will solve the question about the utility of the
SCM ﬂap as an intervention to avoid or prevent
Frey’s syndrome should be multicenter, with a
randomized design, a standardized surgical technique
and experienced surgeons, and clearly deﬁned meth-
ods of evaluation of the syndrome, whether objective
with the Minor’s test (bilateral for intra-individual
comparison) with clear categories to consider it mild,
moderate, or severe or subjective with validated
scales and a long-term follow-up. Because cosmetic
appearance is an important outcome, it should also be
assessed using validated tools, including multiple
evaluators (patients, physicians, and a third party) to
determine the true effect. All these measures must be
assessed in a blind fashion by surgeons not involved
in the surgical procedure. This trial should also have
a sample size that could answer this question deﬁni-
tively and avoid a lack of power. This sample size
could be calculated based in the subjective outcome,
in accord with the new suggestions of outcomes
research, because this is what really determines
patients’ outcomes. The minimum follow-up should be
of 12 months, and the comparison of outcomes should
be made after the same follow-up time for all patients
to avoid recall bias.
In conclusion, the evidence reported on the use of
the SCM muscle ﬂap remains inconclusive, when used
as an intervention in parotid surgery to prevent Frey’s
syndrome, and its effectiveness as a prevention can be
resolved only by a well-constructed and controlled RCT.
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